



Media Contact
Dan McFadden
dmcfadden@oculusis.com
(425) 836-3103

OCULUS INNOVATIVE SCIENCES OPENS EUROPEAN OFFICE AS COMPANY SEEKS CE MARK APPROVAL OF MICROCYN 60 DISINFECTANT AND ANTISEPTIC

Theo Spangenberg, newly appointed European marketing director, to oversee introduction of “disruptive” disinfectant technology to European markets.

PETALUMA, CA (September 9, 2003)— In anticipation of the CE Mark approval in 2004 of the highly regarded Microcyn 60 disinfectant and antiseptic, Oculus Innovative Sciences (www.oculusis.com) of the United States this week opened its European headquarters in Antwerp, Belgium. The offices, to operate under the direction of newly appointed European marketing director, Theo Spangenberg, will house all European sales and marketing. Eventually, manufacturing facilities will be located there as well.

Microcyn 60 disinfectant/antiseptic technology has proven to safely eradicate all viruses, bacteria, spores and molds within 60 seconds. Utilizing patented technology, Microcyn 60 is far more effective and safe than traditional disinfectants and antiseptics currently in use. Due to its non-toxic nature, Microcyn 60 was approved in July of this year by the Mexican Ministry of Health as both a disinfectant (to be used to disinfect hard surfaces and medical instruments) as well as an antiseptic (to be used on patients for the irrigation of wounds and in pre-operative skin preparation).

“We see the approval of Microcyn 60 in Mexico as an important step in providing critical supporting data for the European regulatory approval process,” said Hoji Alimi, CEO and founder of Oculus Innovative Sciences. “This data, in tandem with Theo Spangenberg’s exceptional understanding of the European medical device and pharmaceutical markets, will allow us to come out of the blocks at full speed as we seek European approval.”

About Oculus

Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative services and technologies that can improve patient health worldwide. The company has at its foundation two wholly owned subsidiaries, MicroMed Consulting Services and AquaMed Technologies. Oculus has

overseen the evolution of the Microcyn 60 disinfectant from technology to product as well as the development of an anti-cancer drug (L3) that shows promise in the prevention of many aggressive cancers including cervical cancer and melanomas. This same L3 compound has great potential in other applications based on its cell growth inhibition characteristics such as the drug-eluting stent products reducing restenosis. For more information, please visit us at www.oculusis.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.